REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
9.14
+0.45 (5.18%)
At close: Mar 4, 2026, 4:00 PM EST
9.41
+0.27 (2.95%)
After-hours: Mar 4, 2026, 7:59 PM EST
REGENXBIO Employees
REGENXBIO had 353 employees as of December 31, 2024. The number of employees increased by 9 or 2.62% compared to the previous year.
Employees
353
Change (1Y)
9
Growth (1Y)
2.62%
Revenue / Employee
$456,992
Profits / Employee
-$504,008
Market Cap
462.70M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 353 | 9 | 2.62% | 353 | 0 |
| Dec 31, 2023 | 344 | -57 | -14.21% | 344 | 0 |
| Dec 31, 2022 | 401 | 29 | 7.80% | 401 | 0 |
| Dec 31, 2021 | 372 | 66 | 21.57% | 372 | 0 |
| Dec 31, 2020 | 306 | 49 | 19.07% | 306 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 650 |
| Vanda Pharmaceuticals | 533 |
| 4D Molecular Therapeutics | 227 |
| Kyverna Therapeutics | 129 |
| Solid Biosciences | 100 |
| Invivyd | 100 |
| Verastem | 78 |
| Lineage Cell Therapeutics | 77 |
RGNX News
- 18 hours ago - REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - PRNewsWire
- 2 days ago - REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses - PRNewsWire
- 2 days ago - REGENXBIO to Participate in Upcoming Investor Conferences - PRNewsWire
- 7 days ago - REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - PRNewsWire
- 8 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2026 in REGENXBIO Lawsuit - RGNX - PRNewsWire
- 19 days ago - Regenxbio: Cautiously Bullish After FDA Setbacks - Seeking Alpha
- 22 days ago - FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment - Benzinga
- 23 days ago - US FDA declines to approve Regenxbio's rare disease drug - Reuters